Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...

Losing weight with anti-obesity medications (AOM) also resulted in decreased alcohol consumption for about half of the ...

The push to develop the first oral GLP-1 receptor drug for obesity is heating up, as four phase 3 drugs race to become the first approved oral treatment for obesity, Global Data reported Dec. 2. Here ...

Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...

Ozempic promotes weight loss by mimicking the GLP-1 hormone the body naturally produces after eating, so users feel full for ...

GLP-1RA medications in preadolescents and adolescents were concentrated among those with diabetes, obesity, mood disorders, and anxiety.

Other work primarily only included glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among individuals with substance use disorders. We also compared GLP-1 RAs to metformin and ...

Most common exclusion criteria were major depressive disorder, malignant neoplasms, liver disease, uncontrolled HTN ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

Target RWE, a leader in real-world evidence solutions in liver disease, presented important research on the use of ...

USA: A recent study, published in JAMA Network Open as a research letter, highlights a significant link between anti-obesity ...

LANGHORNE, PA — Amplity Health shared valuable findings from its latest study on GLP-1 receptor agonist (GLP-1 RA) usage ...